Mitral valve replacement The choice of which valve type to use depends upon the patient's age, medical condition, preferences with medication, and lifestyle. New Developments (2014 -2017): Transcatheter mitral valve replacement or TMVR involves human heart mitral valve replacement without recourse to open-heart surgery. TMVR treats mitral valve stenosis and/or mitral valve regurgitation leading to mitral insufficiency. TMVR, initially developed by the company Tendyne (a subsidiary of Jean Boulle Medtech Ltd) for open-heart high risk patients is expected to replace traditional mitral valve replacement surgery in the longer term. The Tendyne mitral valve is placed inside a beating heart via a transcatheter at
Mitral valve annuloplasty the native annulus and some of its natural dynamics. The goal of semi-rigid rings is to maintain coaptation and valve integrity during systole, while allowing for good hemodynamics during diastole. Rigid rings are designed to provide rigid support in large dilation and under high-pressure. Annuloplasty devices usually come in different sizes. The surgeon can estimate the dimensions of the patient’s mitral valve and decide on an appropriate ring size. Depending on the disease etiology, different approaches are taken. Surgeons can decide to "undersize" the device, "truesize" the device, or "oversize" it. Annuloplasty devices are classified by the U.S. Food and